Another once-a-week adjunctive injection is comprised of 1 cc of ACTH Gel,
40 units per 5 cc bottle or vial; .5 cc dexamethasone acetate, 4 mg per 30 ccbottle; and .5 cc triamcinolone acetonide, 40 mg per ml from a 5 ml bottle. A good cancer test is the one for Carcinoma Embryonic Activity (CEA)
performed once a month or more. The normal reading for a non-smoker is 2.5;
normal for a smoker is 5.0. Cancer patients taking the DMSO-hematoxylon-dextrose solution should have
kidney function tests of their urine (creatine clearance and BUN) performed
biweekly. They should always drink plenty of fluids. If swelling occurs, the
physician should prescribe Diuril or some other diuretic. Taking vitamin supplements, especially vitamins A, C, E, and D, is essential. Carrots should be eaten every day, in particular for the treatment of liver cancer. Absolutely no liquor, wine, or beer should be consumed. And, realize that smoking
not only retards healing but may have been a contributing source of causing the
condition initially. The DMSO-hematoxylon-dextrose solution should be administered to the
cancer victim daily until a reasonably low CEA test reading is obtained. CASES OF CANCER CURED WITH HEMATOXYLON AND
DMSO
I mentioned that Dr. Tucker had not published the results of his research and
treatment since 1968 because of peer pressure and fear of 
being removed from
medical practice. But this didn’t completely deter him from attempting to heal
those few who made appeals to him for help. For example, two more patients were
successfully treated for large-cell lymphosarcoma. One lived for eight years after
treatment and finally died from a heart attack, as had a previous lymphosarcoma
case. The other is still alive and well today. In the latter case, Alva Ruth Wilson of Porter, Texas, then age thirty-eight,
learned that she was the victim of disseminated large-cell lymphosarcoma in
January 1972. She had sizeable tumors in her lungs, the common iliac arteries, and
the lymph nodes around her aorta. Patients with lymphosarcoma (the kind of cancer that killed the Shah of Iran)
experience a malabsorption syndrome, a clinical state resulting from impaired
assimilation of nutrients from the small bowel. The victim becomes chronically ill
and emaciated, with pale mucous membranes and dry scaly skin that becomes dark
in color. Blood pressure drops. Fluid accumulates in the abdominal cavity, which
swells disproportionately. Anemia develops, and the cancer cells infiltrate thebone marrow. The patient suffers destruction of normal lymph node architecture
and invasion of the node capsules and adjacent fat by characteristic
lymphosarcoma cells. Death in a relatively short time is predictable. Mrs. Wilson had the maximum amount of chemotherapy she could take for one
month and then chemotherapy and radiation together for another month. Still, the
tumors continued to spread and chemotherapy had to be discontinued because of
its awful side effects. One of these was the development of dangerous leukopenia,
a condition in which the total number of white blood cells in the patient’s
circulating blood was far less than normal. She practically lost her immunity to
infection. As a life-threatening chemotherapeutic side effect, Mrs. Wilson’s white
blood count dropped too far below the lower limit of 5,000 per cubic mm. One year later Tucker began hematoxylon and DMSO injections intravenously
for the woman. They were given every other day from January 1973 through
January 1974. All evidence of her tumors disappeared, and they have not recurred
to the present time. Tucker followed Mrs. Wilson’s progress continually; she is
perfectly well today with no side effects from the treatment or from the tumor. In another case, Elroy Guerro of Houston, forty-one years old, had a
lymphosarcoma of three years duration. After full treatment with maximum
radiation and chemotherapy, the opinion of the radiologist was that the patient had
no chance to survive longer than a few more months. He had involvement of the
mediastinal lymph nodes. This patient was treated by intravenous injections of hematoxylon and DMSO,
2.015 g every other day from December 1971 to March 1972. By the end of the
injection therapy, the tumor had disappeared and Mr. Guerro quit the treatment. Tucker last heard from him in December 1978 and learned that the man was in
excellent condition. There was no evidence of recurrence and no side effects from
the medication. Eventually, when Tucker asked about the patient from his former employer, the
Ideal Engineering Company, the personnel office advised him that Guerro had died
of a heart attack in April 1980, eight years after he had completed the DMSO
treatment for deadly lymphosarcoma.Figure 11.1
 Photograph of Frank T. Guiddy, age 44; note large tumor
lymphosarcoma of the neck. A third patient was less fortunate. Frank T. Guiddy of Kennedy, New York,
age forty-four, was admitted to Memorial Baptist Hospital in Houston in a terminal
lymphosarcomatous state. He had an obvious tumor, entirely surrounding his neck,
lying just under the skin (see 
Figure 11.1
). Mr. Guiddy had been treated five years
previously with maximum radiation and chemotherapy. The traditional cancer
treatments 
had brought on severe side effects, mainly absence of white blood cells
in the blood stream. Every day for three weeks, 2.015 g of hematoxylon and DMSO combination
solution was injected intravenously into the patient. The tumor in his neck
decreased in size from 22.5 inches (in) to 18.75 in (see 
Figure 11.2
), returning
Guiddy’s neck to normal appearance. Unfortunately, this man was so riddled with lymphosarcoma, his body was
totally assaulted by the process. He died at the hospital September 23, 1980. Autopsy showed that he suffered with cancer in almost every organ of his body.Lymphosarcoma involved the man’s cervical lymph nodes, retroperitoneal and
abdominal nodes, membranes around his heart, pancreas, left and right lungs,
spleen, the entire gastrointestinal tract, kidneys, adrenal glands, and especially his
liver, which weighed an immense 3,400 g. He died in bed from liver failure a week
after the photograph shown in 
Figure 11.2
 was taken. His liver was a solid mass of
dead lymphosarcoma. The DMSO-hematoxylon material had enough anti-tumor
quality to destroy the enormous 
masses of lymphosarcomatous growth permeating
the man’s body. If Guiddy had had near-normal organs or at least a functioning
liver, it’s likely he would have survived. But he did not. Figure 11.2
 Frank T. Guiddy after receiving three weeks of hematoxylon and DMSO
treatment. Note the marked decrease in the size of the lymphosarcomatous tumor. MODES OF ADMINISTERING DMSO AND HEMATOXYLON
Cancer of the cervix in the preterminal stage receives the greatest benefit only
from local application. The symptoms become less severe. There is very little
local regression of the tumor itself in advanced squamous-cell carcinoma of the
cervix. However, the patient feels marked relief of pain and a diminution ofbleeding and odor, especially when the DMSO-hematoxylon solution follows local
radiation treatments. Vaginal packing with a 15-percent concentration of the Tucker solution has
been found to be most effective in controlling hemorrhage and odor from
irradiation slough. A small saturated pack is placed against the cervix and left for
three hours and then removed. Topical application has been used in many open lesions of malignancies with
encouraging results. A 15-percent solution of hematoxylon and DMSO is made
fresh and applied over the sloughing malignancy. Tucker suggested that the doctor
should dab the liquid onto the lesion with cotton-tip applicators and, if possible,
not cover or dress the area. Often a dressing with the solution causes an irritation
of the growth and some increase in its size. No toxicity has been noted by this
method’s use. In the administration of the solution intravenously or intra-arterially, the
parenteral liquid agent carrying the hematoxylon and DMSO into the blood vessels
that Tucker preferred is 5 percent dextrose in saline. This parenteral agent should
be started first and when the desired rate of drip is established, then the DMSO-
hematoxylon solution is instilled directly into the bottle—not into the tubing. The
resultant infusion solution should be a pale yellow to green. In the event the
solution turns red, this means hematoxylon has oxidized and should be discarded. A fresh solution must be made up for the infusion. The intravenous rate of injection should not exceed forty drops per minute. Care must be taken to prevent any of the solution from escaping into the
subcutaneous tissue. Otherwise the patient is likely to feel a burning sensation
from activation of the underlying nerve endings. Also, such poor technique
invariably causes a periphlebitis (inflammation of a vein), which damages the vein
for future use. Incidentally, even if the solution has escaped into the underlying
tissue, it has never caused a slough (death of tissue). Too rapid administration results in the patient experiencing shortness of breath
and frequent rapid breathing. In the case of large tumor masses, a fever reaction
often occurs. Tucker believed that this feverishness is due to rapid absorption of
dying tissue. If fever does come on, the treatment should be discontinued and
restarted at a later date with a greatly reduced dose of the solution. The antidote
for fever is to give aspirin by mouth and to inject Demerol intramuscularly. The
Demerol must be given immediately as the intravenous DMSO-hematoxylon
solution is unhooked from the patient. In intra-arterial injections, the same caution should be used as with intravenousinfusion. The physician starts the parenteral solution first and establishes a regular
amount of instillation before adding the DMSO-hematoxylon into the solution
bottle. This method is rarely indicated and should be done with extreme caution. LABORATORY INVESTIGATION OF DMSO USEFULNESS
FOR SKIN CANCER
The effects of dimethyl sulfoxide for the treatment of skin cancer are in some
respects similar to those of the skin substances, retinoids. As we know, DMSO
has the ability to penetrate cellular membranes and to enhance the penetration of
other molecules. Three physicians/biochemists stated in their 1983 published
paper, “It may be reasonable to assume that DMSO treatment results in
differentiation of cells, possibly through membrane-mediated events. This may be
of importance for the study of the carcinogenic process. The release of a certain
amount of lysosomal enzymes [natural chemicals that act within and on the
organelles called lysosomes] to the extracellular space is a normal function of the
cell (Hickman and Neufeld, 1972), and a certain release of the cytoplasmic and
lysosomal enzymes to the extracellular space is not necessarily deleterious for the
cells (Volden, Haugen, and Skrede, 1980).”
The purpose of the three doctors’ investigation was to study the possible
effects of DMSO on methylcholanthrene-induced skin cancer. Methylcholanthrene
is a toxic agent—a carcinogen—that causes excessive mutagenesis (subdividing)
of cells. Since they saw that the uptake of enzymes from the cellular organelles—
the lysosomes—took place by cultured cancer cells and involved a cellular
membrane receptor process, the effects of the carcinogen, they decided to study
HeLa cells and DMSO. HeLa cells are human cancer cells maintained in tissue
culture since 1953, originally excised from the cervical carcinoma of a patient
named Helen Lane. The cytostatic effect of a medication—that is, the 
medication’s
effect on the status of cells—may be determined by measuring the
ademosinetriphosphate (a natural chemical produced within the cells) of these
HeLa cells by means of the laboratory method of bioluminescence. Bioluminescence is a qualitative analysis of a substance in a compound by
visualizing its color in a hot flame. The three researchers measured the DMSO
solvent on the rate of secretion of lysosomal enzymes and lactate dehydrogenase
from the HeLa cells. Their conclusion was that DMSO has a therapeutic use for
skin cancer. 2HOW THE ANTI-CANCER DMSO SOLUTION WORKS
Thomas D. Rogers, Ph.D., under the supervision of Vernon Scholes, M.D.,
performed experimental work in the cancer research department at the North Texas
State University to determine how Dr. Tucker’s anti-cancer DMSO solution
works. Figure 11.3
 shows a controlled lymphosarcoma tumor in a DBA/1J pure line
female mouse. The tumor has not been treated and has been growing for eleven
days between the skin and the muscles of the abdomen. This lymphosarcoma
grows so rapidly, it has no opportunity to metastisize before destroying the animal. Figure 11.4
 shows another DBA/1J mouse injected intraperitoneally with the
Tucker solution at the same time as the mouse in 
Figure 11.3
. In this second
mouse, the tumor has been present for fourteen days, but it has hardly grown
because the DMSO-hematoxylon solution is destroying the tumor. Notice that the
DMSO-hematoxylon has an affinity only for the tumor and has flowed nowhere
else in the mouse’s body. Although the solution was injected into the abdominal
cavity and the tumor lies in the subcutaneous tissue, the dye substance found its
way to the tumor through the mouse’s blood stream. Figure 11.5
 shows an electron microscopy study of the large-cell
lymphosarcoma. The cancer cells are surrounded by ground substance or
interstitial material that looks like ground glass. This is protoplasm that goes into
the cell and feeds the cancer. If the nutritional protoplasm is eliminated, the cancer
cell starves to death. Figure 11.6
 shows that the ground substance around the lymphosarcoma has
been destroyed. The cancer cells are separating and dying. Lymphosarcoma death
is taking place because of lack of nutrition. You can see that the ground glass-like
interstitial material is gone because of the action of the DMSO-hematoxylon
combination solution. The host survives, but the cancer does not.Figure 11.3
 An example of a non-treated tumor-bearing mouse with an 11-day tumor.Figure 11.4
 A photograph of a DBA/1J mouse with a 14-day tumor, showing the affinity of the tumor for
the hematoxylon, which is stained, along with the tumor, with no staining of any other tissue.Figure 11.5
 An electron micrograph showing a portion of the nucleus and cytoplasm (material outside of a
cell nucleus) of the untreated tumor (
Figure 11.3
). All membrane systems are very distinct and there is an
abundant polyribosome aggregate (mass of organelles) distributed in the cytoplasm. X6, 250Figure 11.6
 An electron micrograph of tumor tissue from the mouse (
Figure 11.4
). Note the breakdown
of tissue structure and separation of cells leading to cell destruction. X6, 250
 
From the studies of Rogers,
3
 we learn that this combination of hematoxylon
and DMSO produces a hematein reaction of oxidation with the tumor cells to
affect the ground substance, which in turn leads to cancer cell death. The DMSO
had no action on the tumor cell itself but remained merely as the remarkable
vehicle it is, penetrating the tissues to carry in the hematoxylon. The hematoxylon
made the ground substance inactive and therefore starved the cancer cells to death. Eli Jordon Tucker, Jr., M.D., was a maverick. He bucked the medical
establishment to bring a possible cancer cure to the medical consumer. But
because he attempted to halt cancer through private research, the physician
traditionalists labeled Tucker a “quack.” To make matters worse, he used, as part
of an anti-cancer compound, a drug that isn’t approved by the FDA for any
purpose other than treating a urinary bladder condition. In the thinking of
traditionalists in medicine, this made the doctor a heretic as well as a quack. But
in the hearts and minds of his patients, Tucker was a hero. Just like Louis Pasteur, who postulated the connection between bacteria and
certain diseases, or Ignaz Philipp Semmelweis, who made obstetricians wash their
hands, E.J. Tucker braved the wrath of the medical establishment. He was hurt by
them, often doubly hurt, especially when his patients were mentally and
emotionally assaulted by righteous, self-serving health professionals who use their
powers to dispense life or death for their own purposes. Dr. Tucker described
such an incident. A three-year-old boy named Clyde Robert Lindsey of Pasadena, Texas, was
brought to Tucker’s office by his mother on January 14, 1970. The child had
diabetes insipidus, which was being treated by the Texas Children’s Hospital of
Houston with injections of Pitressin, an anti-diuretic that controlled the excess
urination the boy experienced. Worse, he was the victim of a particular type of
metastatic endothelioma, also known as Letterer-Siwe disease, which was being
treated by the M.D. Anderson Cancer Institute. Multiple cancer lesions had spread
through the boy’s scalp and over his body. He had draining sinuses from tumors
lodged behind the ears on both sides and from inside. These were solid, palpable
lumps that you could see and feel. Otolaryngologist George Stout, M.D., at the
Houston Eye, Ear, Nose, and Throat Hospital, diagnosed the boy’s condition ashopeless. Such a young patient is known not to live over six or seven years. The mother and son were left destitute by the father, who ran away from his
family because his child had come down with cancer. Little Clyde was not getting
any better, and Mrs. Lindsey wanted Tucker’s 
treatment for him because she had
heard of his particular successful approach. Listening to her pathetic story, the
doctor agreed to give the boy care, but only after he explained to the woman that
the solution was entirely experimental and might do nothing for her son. He
charged nothing for the treatment or for the supplies of solution. Tucker gave her a small dropper bottle of DMSO-hematoxylon mixture and
told her to give the child five drops in distilled water each morning before
breakfast while he still had an empty stomach. The doctor also told her to take the
medicine to one or both of the hospitals and show the medical personnel taking
care of Clyde just what she was having him swallow. Mrs. Lindsey returned the next day totally distraught. Between heavy sobs and
tears, she explained how the Texas Children’s Hospital staff became enraged and
told her never to come back if she used Tucker’s medicine for her son’s cancer. This meant that her supply of Pitressin for treating the little boy’s water diabetes
was completely cut off, since she had no money with which to buy more. This scene took place within earshot of other patients sitting in Tucker’s
reception room. They passed the hat and in a couple of minutes raised $75 for the
mother to buy her child’s diabetic medicine. Since then, the mother has married a fine and respectable man. She has
continued to give Clyde the DMSO-hematoxylon solution all of these years, and
today, he is a big, strong young man of twenty-nine who takes his anti-cancer
medicine every day. Seeing him again, otolarynogologist George Stout expressed
utter amazement that the man was still alive and seemingly so well. Recently I
interviewed Clyde and his mother and confirmed the details of this dramatic
patient history. The addition of dimethyl sulfoxide to the intravenous infusion bottles of cancer
patients who are undergoing biological (non-drug) therapy has become almost
routine today. The pharmaceutical grade of DMSO is broadly adapted by those
unconventionally-practicing physicians with open minds and love in their hearts for
people who come to them for health assistance. In contrast to so-called orthodox
oncologists, the holistic oncologist (and such a physician is rare and should be
cherished) does not experiment on his or her patients with toxic ingredients. Side
effects are almost nonexistent. Indeed, DMSO is nontoxic altogether, offers little
or no side effects, and brings about swift healing qualities for the cancer victim.DMSO—in particular its combination with hematoxylon solution—removes cancer
pain and reduces or eliminates free radical pathology that characteristically is
present in most cancer patients. Any cancer patient who has received
chemotherapy or radiation therapy has, in fact, burdened his or her body with vast
amounts of free radicals as manifested by sores at the corners of lips, metallic
taste in the mouth, dry mouth, loss of head hair, nausea, and more. Drinking a
small quantity of diluted dimethyl sulfoxide will tend to relieve or reduce many of
these free radical symptoms and signs. The 1990s are witnessing a resurgence of interest in dimethyl sulfoxide for the
treatment of cancer, especially hard tumor carcinomas and lymphomas. The patient
who has not subjected himself to chemotherapy or radiation therapy benefits
exceedingly from DMSO intravenous infusions, intramuscular injection, topical
applications, and oral solutions. At the start of the third millenium, in the year
2000, DMSO is predicted to be the salvation of cancer patients worldwide. It is
medicine’s newest therapeutic principle. A further discussion of DMSO therapy for cancer can be found in the book
Coping With Cancer
, by John L. Sessions, D.O., and Morton Walker, D.P.M.,
available by mail order from Freelance Communications, 484 High Ridge Road,
Stamford, Connecticut 06905-3095, (203) 322-1551.CHAPTER 12
Infectious Diseases Respond to DMSO
In April 1980, a nutrition and health counselor, Mrs. Vernice Reed of San
Francisco, sixty-six years old, contracted a severe infection in her mouth. She
sought medical attention from the outpatient department of a general hospital near
her home but was turned away with the admonition that her disorder belonged in
the province of a dentist. The next afternoon the woman’s dentist told her, “Vernice, you have herpes
zoster!”
“Shingles! I don’t believe it,” she said. “Well, you’ve had enough pain, haven’t you?”
“Yes!”
“That’s what it is, a viral infection,” said the dentist. “And I’m sorry, but
there’s nothing we can do for you, especially when herpes hits the mouth.”
Herpes zoster or shingles is a viral nerve infection that produces a painful
inflammation of the sections of nerves emerging from the spinal cord. The
varicella-zoster virus, the same virus that causes chicken pox, is responsible. Fever and prostration frequently accompany the pain. There are associated chills,
gastrointestinal disturbances for three or four days, and a feeling of overall
discomfort. On the fourth or fifth day, characteristic crops of tiny, red, acutely
sensitive blisters appear on the skin. They mostly erupt on the chest, and spread
along one side of the body following the course of the affected nerve. (
Herpes
means “creeping,” and 
zoster
 means “girdle.”)
A form of herpes zoster that inflames the nerves leading to the face and eyes,
such as the type invading Vernice Reed’s mouth, is especially dangerous because
it may damage vision. An ordinary attack of shingles runs its painful course in a few days or weeks
and does not leave residual difficulties. One attack will 
usually confer immunity. In some cases, most frequently in elderly people, there is a persistence of pain
called postherpetic neuralgia that may be disabling, and which hangs on long after
the blisters of shingles disappear. Mrs. Reed’s dentist was correct in this case. There is no specific therapy forherpes zoster. Sometimes corticosteroids help if given before the symptoms
become established; otherwise, the patient just has to wait for the disease to run its
course. Mrs. Reed decided to experiment on her own with DMSO, for she keeps it on
hand all the time as a first-aid remedy. She took one teaspoonful of the full
strength concentration and combined it with one teaspoonful of distilled water to
make a 50 percent swabbing solution for her whole mouth and upper throat. She
swabbed and gargled three times through the day and by the evening she had no
more pain. “The next day I did the swabbing again,” Mrs. Reed said. “I combined aloe
vera with the mixture this time, because aloe vera eases the stinging that
accompanies use of DMSO. The following day there were absolutely no more
blisters. I didn’t need to swab anymore. My mouth has never had any blisters
since.”
DMSO FOR HERPES ZOSTER: A STUDY OF FORTY-SIX
PATIENTS
Whether you call it shingles or herpes zoster, the disease is a pain for the victim. The condition is especially disconcerting when it appears around the breast area of
women and the belt area in men, probably because of constant friction of clothing
in those particular places. If it strikes the face or rises in the scalp, the symptoms
are a terrible itch and searing pain. In 1971, Dr. William Campbell Douglass, now of Clayton, Georgia, did a
clinical investigation on the local application of DMSO for patients suffering with
herpes zoster and had some fine results. Table 12.1
 summarizes the study. It
illustrates that the sooner DMSO treatment is given for herpes zoster, the better the
skin lesion response will be. And it’s probably true that when the condition is
treated with DMSO early enough in the acute phase, the postherpetic neuralgia
syndrome won’t occur either. If you are going to use DMSO to relieve the symptoms of shingles, I suggest
you do it under the supervision of a physician following a certain procedure. The
material is applied directly to the skin lesions. Put the 75-percent liquid strength
onto the sensitive area as often as it is tolerable, realizing that it will sting. If the
blisters are too sensitive to accept this high-strength DMSO, dilute it with water to
bring down 
the concentration. Experiment with how much water to add. You mayfind it comforting to sit in front of a revolving fan to cool the burning feeling from
DMSO application on the lesions. Caution: While it is less effective, I recommend
only a 50-percent solution be used for treating the face, neck, and scalp. In his study, Dr. Douglass frequently combined dexamethasone (Decadron)
with DMSO. There was no noticeable difference with this drug combination as
compared to the DMSO used alone. In Table 12.1, the spinal areas are listed
merely as location markers showing the approximate place the herpes zoster was
present. Note the unusual cases where good results were acquired even after
patient number 24 had the condition for four-and-a-half years and patient number
37 had it for one-and-a-half years. DMSO has become a specific remedy to overcome the symptoms of herpes
zoster, particularly to relieve the pain that follows the course of the involved
nerve. Those patients who have itching but no neuralgia do not feel much relief of
the itching; in fact it may increase. In general, DMSO applied to herpes zoster with
skin eruption appears to shorten the course of the disorder and to prevent
postherpetic neuralgia. AN ENGLISH STUDY OF SHINGLES
Just before the Douglass study took place, a research group in Oxford, England,
investigated the use of a combination of the antiviral drug, idoxuridine, and DMSO
for treating shingles. Although systemic idoxuridine was tried against this viral
nerve disease with equivocal results, the Oxford investigators reasoned that, since
the varicella-zoster virus is related to the herpes simplex virus, and since DMSO-
idoxuridine has been useful against herpes simplex lesions on the skin and mucous
membranes, it was worth a try. The idea was to prevent virus replication, thus
ameliorating the disease and, not incidentally, the pain. The English investigators’ trick worked. Continuously applied 40 percent
idoxuridine in purified dimethyl sulfoxide clears up the herpes zoster lesions
quickly. The continuous administration is achieved with a piece of lint, soaked in
the drug, placed over the vesicles, and kept on the skin by a gauze bandage. The
lint is resoaked daily. “The patients were delighted, for the pain disappeared within a median of two
days. Healing also appeared to be accelerated,” the researchers reported in the
British Medical Journal
 of December 26, 1970. 1
 Some skin peeling occurred after
treatment was ended, but only one subject in this uncontrolled trial had asecondary bacterial infection. Table 12.1
 DMSO Study on Herpes Zoster (H.Z.) and Postherpetic Neuralgia (P.H.N.) RESULTS
William C. Douglass, M.D. Patient
Diagnosis
Duration
Location
RX
Good
Fair
Poor
Inconclusive or Unknown
1
Herpes Zoster w/Neuralgia
7
 days
T-10
DMSO 90%
X
 
 
 
2
Post Herpetic Neuralgia
I
1
⁄
2
 yrs
T-5
DMSO 90%
 
 
X
 
3
P.H.N. 14 days
T-10
DMSO 90%
X
 
 
 
4
H.Z. w/Neuralgia
7 days
T-14
DMSO 90%
w/Decadron
X
 
 
5
P.H.N. 4 mo. T-8
DMSO 70%
 
X
 
 
6
P.H.N. 14 days
T-12
DMSO 90% w/Decadron
X
 
 
 
7
P.H.N. 3 wks
T-5
DMSO 50% w/Decadron
X
 
 
 
8
H.Z. 3 days
5th cranial
DMSO 50% w/Decadron
X
 
 
 
9
H.Z. 7 days
L-5
DMSO 90% w/Decadron
 
X
 
 
10
H.Z. 4 days
L-5
DMSO 90%
X
 
 
 
11
H.Z. 5 days
T-5
DMSO 50% w/Decadron
X
 
 
 
12
H.Z. w/Neuralgia
7 days
T-6
DMSO 9% w/Decadron
X
 
 
 
13
H.Z. w/Neuralgia
4 days
C-5
DMSO 50% w/Decadron
X
 
 
 
14
P.H.N. 6 mo. T-5
DMSO 90% w/Decadron
X
 
 
 
15
P.H.N. 30 days
T-4
DMSO 90%
X
 
 
 
16
P.H.N. 5 mo. 5th cranial
DMSO 50% w/Decadron
X
 
 
 
17
P.H.N. 5 mo. T-4
DMSO 90% w/Decadron
X
 
 
 
18
H.Z. 5 days
L-l
DMSO 90% w/Decadron
X
 
 
 
19
H.Z. 2 days
T-3
DMSO 90% w/Decadron
X
 
 
 
20
H.Z. 5 days
T-7
DMSO 90%
 
 
 
X
21
P.H.N. 8 wks
T-12
DMSO 70%
X
 
 
 
22
Neuralgia Post Traumatic
6 mo. 5th cranial
DMSO 70% w/Decadron
X
 
 
 
23
H.Z. 1 day
L-4
DMSO 90% w/Decadron
X
 
 
 
24
P.H.N. 4.5 yrs
Left occipital N.
DMSO 70%
X
 
 
 
25
P.H.N. 3 yrs
T-8
DMSO 90% w/Decadron
 
 
 
X
26
P.H.N. w/Neuralgia
3 wks
T-10
DMSO 70%
X
 
 
 
27
H.Z. w/Neuralgia
2 wks
T-7
DMSO 70%
X
 
 
 
28
Neuritis
1 mo. Dorsum Rt. Foot
DMSO 70%
 
 
X
 
29
H.Z. w/Neuralgia
1 wk
T-4
DMSO 70%
 
X
 
 
30
H.Z. w/Neuralgia
2 wks
T-4
DMSO 70%
X
 
 
 
31
P.H.N. 18 mo. L-5
DMSO 70%
 
 
X
 
32
P.H.N. 4 mo. L-l
DMSO 90% w/Decadron
X
 
 
 
33
H.Z. w/Neuralgia
2 days
Ulmar N.
DMSO 90% w/Decadron
X
 
 
 
34
P.H.N. 2 mo. C-7
DMSO 70%
X
 
 
 
35
P.H.N. 2 wks
L-l
DMSO 90% w/Decadron
X
 
 
 
36
H.Z. w/Neuralgia
1 wk
5th cranial
DMSO 50%
 
X
 
 
37
P.H.N. l
1
⁄
2
 yrs
T-7
DMSO 90% w/Decadron
X
 
 
 
38
H.Z. w/Neuralgia
6 days
T-10
DMSO 70%
X
 
 
 
39
P.H.N. 10 days
T-5
DMSO 90% w/Decadron
X
 
 
 
40
H.Z. w/Neuralgia
2 wks
T-5
DMSO 70%
X
 
 
 
41
P.H.N. 4 mo. 5th cranial
DMSO 50%
X
 
 
 
42
H.Z. w/Neuralgia
10 days
T-8
DMSO 90% w/Decadron
X
 
 
 
43
P.H.N. 3 yrs
5th cranial
DMSO 50%
X
 
 
 
44
H.Z. 1 wk
T-l
DMSO 90%
X
 
 
 
45
P.H.N. 3
1
⁄
2
 yrs
T-l
DMSO 90%
 
X
 
 46
H.Z. 4 days
T-10
DMSO 90% w/Decadron
X
 
 
 
The English investigators tried to do a double-blind study by using the 40
percent combination of drugs against DMSO alone, and against salt solution with
garlic added. The garlic was supposed to simulate the characteristic odor of
DMSO, thus preserving the double-blind feature of the test. I doubt that this can be
done, since DMSO has such a distinct odor. Double-blind or not, either the
investigating clinician or the subject of the test or both are likely to recognize
which solution is the placebo. This DMSO-idoxuridine treatment worked even better against the simpler virus
infection, herpes simplex. By itself, DMSO is only moderately successful against
the cold sores (fever blisters) of the simplex virus. Herpes simplex is a viral skin infection causing clusters of red, fluid-filled
blisters on the skin or mucous membranes. The blisters cause burning and itching
sensations for from five to ten days, then dry up and form yellowish crusts that fall
off easily. Herpes simplex is a latent disease that recurs suddenly within months or
sometimes years. It is triggered by exposure to sunlight, emotional upset, intestinal
infections, pregnancy, or sexual intercourse. It is, in fact, a venereal-type 
disease,
transferred by personal contact, although it may occur for no apparent reason. The oral herpes simplex virus type 1 attacks the face, usually near the mouth
or on the lips. The genital type, herpes simplex virus type 2, infects the external
genital organs; in women it often breaks out in the vagina or on the cervix, and it
has been identified as a probable cause of cervical cancer. The type 2 virus is
spread by coitus. Note to doctors treating the herpes venereal disease: Mixing DMSO with
vitamin C crystals appears to be quite an effective treatment for herpes labialis or
other genital herpes. In an interview with Orville J. Davis, M.D., formerly in medical practice in
San Diego, California, he said he had success with this vitamin C combination for
herpes simplex and herpes zoster, too. “What we did was give 60,000 milligrams
of vitamin C by intravenous injection, and paint the lesions with the DMSO-
vitamin C solution. You have to keep the lesions wet. After two-and-a-half hours
of IV, the redness is gone.”
One woman, age fifty-eight, that Dr. Davis had treated, got rid of her scalp
herpes simplex problems permanently within three days. The lesions on the right
side of her head ran from the back of her head, over her scalp, and down to her
right eye. She could have had an ophthalmic herpes—highly dangerous to eyesight
—if the vitamin C and DMSO did not work so fast.RESPIRATORY INFECTIONS ELIMINATED WITH DMSO
In Chile, respiratory diseases rate among the principal causes of death for children
less than one year old. Doctors in private medical practice there find it necessary
to hospitalize babies most often for acute inflammatory obstruction of the lower
respiratory tract. For this reason, Chilean pediatricians have been on the lookout
for some technique or medication to act with a good, fast therapeutic effect. Three
research physicians at the Manuel Arriarn Pediatric Hospital in Chile have found it
in DMSO spray. Rodolfo Burdach, M.D., head of the Department of
Bronchopulmonary Diseases, Aristides Zuniga, M.D., ear, nose, and throat
specialist, and Santiago Rubio, M.D., pediatrician, ran a study using DMSO on
babies having respiratory problems. Generally, the first sign of acute inflammatory obstruction in a baby is the
sudden appearance of progressive respiratory difficulties. These difficulties take
the form of snoring while awake or sleeping, and repeated 
coughing. The baby’s
lung problem is associated with swelling infiltration and fibroid death of the
bronchial lining. Great accumulations of mucous secretion develop in the bronchial
channels leading into the lungs. This often provokes secondary bacterial infection. The three research physicians labeled the entire syndrome as “bronchiolitis.”
Bronchiolitis should not be confused with bronchopneumonia, asthma,
whooping cough, interstitial pneumonitis, obstructive laryngitis, or acute
obstructive bronchitis. These conditions were treated as well, but bronchiolitis was
the three doctors’ main area of interest. As indicated in 
Table 12.2
, they treated a group of thirty babies suffering from
bronchiolitis and acute obstructive bronchitis with a DMSO spray containing
biguanide hydrochloride, hydrocortisone, n-propylcarbinol, and lidocaine as added
ingredients. In Chile, this combination is sold commercially as “Plus-Par.” The
Plus-Par product is bactericidal and virustatic. It had found use previously for
treating wounds, chronic ulcers, recent ulcers, herpes zoster, burns, and fungus
infections of the skin. The spray is applied on the affected skin area once or twice
a day. Table 12.2
 Distribution of Patients According to Diagnosis
Diagnosis
Number of Control
Cases
Number of DMSO Spray
Cases
  Bronchiolitis
19
14  Bronchopneumonia
3
7
  Atelectasis
1
1
  Pneumonitis
5
6
  Obstructive
bronchiolitis
2
2
 
—
—
  Total Patients
30
30
The researchers adapted the spray for respiratory disorders. Their method of
application consisted of vaporizing the baby’s throat with DMSO spray for a few
seconds. The doctors coated the area with approximately 2 ml of the compound in
order to uniformly cover the lower part of the larynx to the mouth cavity and the
region of the tonsils and palate. One spray application was made twice daily until
some therapeutic response was obtained. Then they increased the daily
applications from one to four. In ten cases a single application was sufficient; two
sprayings were used for nine cases; three sprayings in five cases; and six cases had
vaporizing four times. In addition, these cases received antibiotics. The young
patients were observed every thirty 
minutes and their physical changes were
recorded as to temperature, respiratory frequency, and pulse rate. Results of these
clinical trials are recorded in 
Tables 12.2
 and 
12.3
. Besides the improvements recorded in 
Table 12.3
, other signs of favorable
responses in the babies were: the sticky bronchial secretion, which tends to dry
into a troublesome respiratory obstruction, lost its thickness and became more
fluid so that the patient could cough it out; and the rapid heartbeat and prolonged
exhalation associated with respiratory infections tended to disappear shortly after
administering the DMSO spray. Summarizing, the three doctors wrote, “It may be said that the use of DMSO
spray in this clinical experience has been efficacious in the cases of bronchiolitis
and obstructive inflammatory bronchial syndromes. The therapeutic response was
more rapid and significant in children treated with DMSO spray than in those of
the control group, who received medication of antibiotics, corticoids, and stayed in
croupettes [humid oxygen chambers]. In view of these favorable changes, the time
of permanence in the croupette can be considerably reduced or its use may be
dispensed with altogether. “The advantages of this therapy are its easy application, its rapid action, and
the fact that no special instruments or apparatus are required. We therefore believethat this is a therapeutic resource which is particularly indicated in rural and in
remote areas, where the physician has no specialized services available and where
the treatment can be used on a large scale when the children are threatened by an
outbreak of such an epidemic.”
2
Table 12.3
 Variation Mean Percentages in the Immediate Effect With DMSO Spray
Variations
Percentages
Sensorial and general improvement
80%
Decrease of adenoids
76%
Decrease of intercostal retraction
75%
Change in chest sounds
80%
THE RELIEF OF TINNITUS
There are two kinds of sounds taken into account in medicine. One is the bruit, a
noise that may be heard by the examiner as well as the 
patient. Then there is a
tinnitus, a subjective experience of the patient in which the perception of sound
occurs in the absence of acoustic stimulus. It is an annoying experience that may
have psychological impact on the victim. Tinnitus may take the form of a buzzing, ringing, roaring, whistling, or hissing
in the ears. Or, it may involve more complex sounds that vary over time. The
sounds might come and go or be continuous, and sometimes there’s an associated
hearing loss. The condition could be a symptom of nearly all ear disorders, including
obstruction of the external auditory canal due to ear wax or foreign bodies, tumors,
other degenerative diseases, or as a reaction to some substance that the individual
is allergic to. Much of the time, tinnitus comes from an infectious process such as
external otitis (ear inflammation), myringitis (inflammation of the tympanic
membrane), otitis media (middle ear inflammation), labyrinthitis (inflammation of
the internal ear), petrositis (inflammation of the temporal bone and its air cells),
syphilis, meningitis, or some other infection. Until now, there has been no specific medical or surgical therapy for tinnitus. But DMSO used together with vasoactive and anti-inflammatory substances has
brought cessation of the sounds to adults of both sexes suffering from this chronic
disease. For fifteen people suffering from chronic tinnitus, DMSO in combination withvasoactive drugs was administered by injection, and DMSO in combination with
anti-inflammatory preparations was applied externally. None of the people had
responded to any other treatment. Any patient that showed psychotic tendencies or
had acoustic trauma or aneurysm was eliminated from the study, because these
problems would cause an erratic reading of the results. A variety of laboratory and physical tests was carried out to determine the
modification of tone, intensity, and character of the tinnitus. The treatment
consisted of one daily intramuscular injection of “Ipran,” a preparation based on
DMSO in combination with buphenine and amino acids. The same investigator
who was part of the Chilean study, Dr. Aristides Zuniga, performed the second
study, in which he took audiometry and tympanic temperature measurements on all
patients before and after the treatment. In addition to the injections, the external ear canal of the particular ear hearing
the irritating sound was treated with 2 ml of a medicinal spray containing DMSO
and anti-inflammatory drugs described as Plus-Par. The spray applications were
made every four days during the entire period of treatment. Even though all of the patients suffered from chronic tinnitus for more than six
months prior to starting the treatment and none had adapted to the noise each
heard, in nine out of the fifteen, the subjective discomfort and head noise
disappeared completely after one month of treatment. In two others the noise
diminished considerably in intensity but did not totally disappear. Four patients
retained tinnitus but described it as changed and sporadic, especially when they
were exposed to the cold in the morning. Patients who had complained of nausea
and positional dizziness from the condition before treatment didn’t have these
sensations after it. They also lost their persistent insomnia, as well as headache,
neurotic anguish, and ear pain. Dr. Zuniga said, “The disappearance of the tinnitus was permanent and no
recurrence of the symptoms was noted on the occasion of the periodic checkups
made during the course of one year. The tolerance of the Ipran injections and
external Plus-Par applications was satisfactory in all cases. The only undesirable
side effects were the garlic odor emanating from the patients undergoing DMSO
treatment and on rare occasions a slight tachycardia (rapid heartbeat) and/or
feeling of nausea shortly after the intramuscular injection. These temporary side
effects can be avoided if the patient remains seated and rests for a short while
after each injection.”
3
Since the early use of dimethyl sulfoxide for the protection of biological
specimens against freezing damage, this chemical has been put to use inmicrobiology. 4
 A bacteriostatic agent, DMSO retards the growth of bacteria. It is
also suspected of being quite a good bactericidal agent, an antiseptic that kills
bacteria. It definitely controls fungi, as was shown by its beneficial effect in
eliminating athlete’s foot, as described in 
Chapter 8
. One of DMSO’s most encouraging characteristics is its ability as an antiviral
agent and a transporter of certain antiviral drugs. It carries antiviral compounds
directly into the cell where they are most effective against intracellular parasites. This is illustrated by its action against the herpes organisms, described earlier. The more recently discovered and unexpected DMSO results against animal
parasites are really exciting to many clinicians. The drug can be administered for
various encysted helminthes (worms). Such hard-to-reach conditions as amebic
abscess of the liver, trichinosis of the striated muscles, schistosomiasis, and other
problems from animal parasites are now treatable by combining DMSO with
antihelmintic compounds. For instance, creeping eruption (cutaneous larva
migrans) has lent itself to experimental therapy with DMSO. 5
,
6
ADDITIONAL MISCELLANEOUS INFECTIONS BENEFITTED
BY DMSO
In 1984, three Russian physicians reported that dimethyl sulfoxide was
incorporated into the program of critical care given to patients suffering from many
different types of infections. As an illustration, they utilized the case history of an
adolescent adult who overcame his infectious process more swiftly by the addition
of DMSO to their medical armamentarium. 7
Reporting in the June 1984 issue of the 
Annals of Rheumatic Diseases
, three
American physicians described their use of DMSO in cases of leprosy resulting in
complications for the patients’ kidneys. Explaining that generalized amyloidosis of
the kidneys can be treated only if the underlying disease is eliminated, they
investigated the role of dimethyl sulfoxide in leprosy associated with secondary
amyloidosis. At first the physicians found that there was no effect on the patients’
creatinine clearance or twenty-four-hour proteinuria of the kidneys when a placebo
using colchicine was employed. However, when DMSO was added to the therapy,
renal function was considerably improved in three patients with moderate kidney
failure. But in those with severe renal impairment (a creatinine clearance of less
than 10 ml per minute), no particular improvement was observed. The
investigators wrote: “These findings point to a beneficial effect of DMSO inhuman secondary amyloidosis when given at an early stage of renal involvement.”
8
DMSO found use for venereal disease complications in 1989. An unusual
localization of lichen amyloidosus (a skin disease) in a patient with lgG k benign
monoclonal gammopathy (a non-malignant immune disease) was reported. After
topical treatment with dimethyl sulfoxide the skin lesions improved, but
histological examination still showed amyloid deposits. 9
The Russians stated in a 1988 published paper that they are routinely instilling
DMSO into surgical wounds to speed their healing and to provide general infection
control. As a result, their surgical patients are finding great advantages from faster
postoperative wound closure. 10
Boosting of the immunity among patients suffering from osteomyelitis (a bone
disease resulting from infection) occurred from the adjunctive use of DMSO, as
indicated in another 1986 Russian study. Their bone infections improved markedly
from a boosting of lymphocytes to fight off the chronic disease process. The
investigators stated in their clinical journal article, “The application of Dimexid
and Dekaris [their 
two brands of DMSO] is shown to give better results in the
treatment of patients with chronic osteomyelitis.”
11
Orchitis, an inflammation of the testis that causes pain, redness, and swelling
of the scrotum, and may be associated with inflammation of the epididymis (part
of the spermatic duct system), usually is caused by infection. It is a condition that
affects one or both testes as the infection spreads down the vas deferens. The
orchitis may develop in mumps, and mumps orchitis affecting both testes may
result in sterility. Treatment of epididymo-orchitis often is by local support and
administration of analgesics for pain and antibiotics for infection. However, a
Russian urologist, Dr. V.N. Glozman, reported in a November/December 1986
Russian journal of urology that his patients suffering with orchitis and epididymitis
benefitted when he added dimethyl sulfoxide to the treatment regimen. 12
As recently as September 1992, biological physicians reported to the
Pharmacological and Biological Therapies panel of the newly created Office for
the Study of Unconventional Medical Practices that DMSO has found use for
infection with HIV, the virus suspected of causing AIDS (acquired immune
deficiency syndrome). This new office of the National Institutes of Health is
looking at DMSO and other unconventional medical practices as a means of
expanding health care in the United States. DMSO has opened up a way to control practically all infections. Medical
scientists must now experiment with the substance in laboratories and clinics todiscover and label its vast storehouse of applications. For this purpose alone,
DMSO should be legalized for use nationally.CHAPTER 13
Misreporting of DMSO for
Scleroderma and Interstitial Cystitis
It was nine years before that Jean Puccio of Washington, D.C., had had a diagnosis
of scleroderma leveled at her. Supposedly this was a death sentence. But on July
31, 1980, Mrs. Puccio sat smiling at the United States Senate Subcommittee on
Health and Scientific Research and told the four presiding senators her story. DMSO was responsible for the woman’s being free of pain at last and able to work
twelve- or thirteen-hour days as a hair stylist. “I had been going for about a year and a half to the military doctors, and they
did not know what my problem was,” explained Mrs. Puccio. “When I finally got
to Walter Reed Hospital, I stayed a week and they did muscle biopsies and nerve
blocks. I was examined by thirty doctors and several civilian consultants. They
told me that I had scleroderma, which I had never heard of.”
Scleroderma, also known as progressive systemic sclerosis (PSS), is a
potentially fatal disorder of the connective tissues, a chronic rheumatic disease of
unknown cause. It is characterized by fibrotic degeneration and blood vessel
abnormalities in the skin, joints, and internal organs (especially the esophagus,
intestinal tract, lung, heart, and kidney). Advanced diffuse scleroderma is unmistakable, but the disease also exists in a
form in which there is only limited skin change, often confined to the fingers and
face. This variant is generally known as the CREST syndrome, which stands for
Calcinosis (lime salts deposited in body tissues, hardening them), Raynaud’s
phenomenon (spasms of tiny arteries), Esophageal dysfunction (blockage of the
food tube), Sclerodactyl (hardening of the skin on the fingers and toes), and
Telangiectasia (swelling of the small blood vessels). The CREST syndrome may
take many years to develop distinctive and fateful internal manifestations. Thus,
the disease may occur in a mild form compatible 
with long life, or it may cause
early death due to heart failure, kidney disease, lung complications, or intestinal
malabsorption with extreme weight loss and weakness. PSS is more common in
women and comparatively rare in children.Learning that she had this serious form of collagen vascular disease, Mrs.
Puccio said to the doctors, “Okay; fine. What are we going to do about it?”
One of the physicians answered, “Unfortunately, there is nothing we can do
about it.”
She wondered, “No medication?”
He said, “No. The best you can hope for is a wheelchair, and within a short
time, you will probably die.”
“I went from doctor to doctor to doctor,” Mrs. Puccio told the Senate
Subcommittee. “I finally found Dr. Jacob through a lady in Pennsylvania. I called
him and went to Portland. Dr. Jacob examined me, and he verified the diagnosis. At that time, I was becoming Oriental-looking; my skin was being pulled back. I
was having difficulty breathing and walking and eating. He put me on topical
DMSO, but it burned my skin, since scleroderma has a tendency to make your
skin tissue thin.”
Senator Edward Kennedy, Subcommittee Chairman, asked about the woman’s
troubles with opening her mouth and her problem with eating, which she had told
him of before the beginning of the hearing. “Because it constricts your tissue, it thickens the tissue, and it makes your skin
so tight you cannot move. It was difficult for me to drive; it was difficult for me to
turn the ignition in my car or turn my body. It was just very difficult. . . . I have a
letter here from my dentist. He could not do any dental work on me for a while. Now, I can open my mouth like anybody else does. . . . I went to Dr. Jacob, and
he gave me the medication, which I brought back to Virginia. I painted it topically,
but it burned my skin. I called him back, and he said, ‘Let us try taking it orally,’
so I started taking it orally. Within about six months my condition reversed almost
immediately. . . . I can do anything anybody else can now. Unfortunately, I have
to be on that drug for the rest of my life.”
Mrs. Puccio also paints on a form of DMSO called 87-2, which was developed
by Robert Herschler (see 
Chapter 5
). This is mixed with different chemical
complexes, including urea. It is almost odor-free. She paints it on her skin at night,
and by morning the odor is gone. She is extremely conscious of the odor. When
she drinks it, she said, she does not go out. “I drink it on Saturday, and I am not
out of the house until Monday evening, because I am conscious of it.”
Her eyes were examined every year for the seven years she used DMSO. “I
have not had problems with my eyes,” said Mrs. Puccio. Her statement about
experiencing no eye problems is significant, as we shall see. On April 9, 1980, writing to United States Representative Claude Pepper whohad chaired the House Select Committee on Aging to investigate “DMSO: New
Hope for Arthritis?” Lillie Forister of Artesia, New Mexico, told of her particular
form of arthritis—scleroderma. Mrs. Forister wrote:
I was twenty-five years old with a five-year-old daughter when I was told I
have scleroderma and that there is no cure and very little help for it. About the first thirteen years, it wasn’t too bad. I had ulcers on my
fingertips. I only had pain while the ulcers were healing, and being cold
during the winter months. But the last six years have been something else. In 1974, I had an
amputation of my first toe. And then in 1979, I lost two more. I am
enclosing some pictures so you can get an idea of what has happened to
me. The last five years, during the winter months, the only way to get by is
to live on pain pills and then it doesn’t do the job, just takes the edge off. You lose weight and walk the floor at night, because you can’t sleep for
the pain. The pain is with you day after day ’til you don’t think you can
take it any more. Then the first part of 1979, I started having chest pains and trouble
with my lungs. I couldn’t even clean up one room without sitting down and
resting. I’ve always been able to take care of myself. And it’s very hard
for me to have to accept help from others. Another thing about this
disease, if you can’t get health insurance or [even] if they will [give you
insurance], it’s so high you can’t afford it. That’s the bad side of scleroderma. Now for the good part, the only
ray of hope I’ve had in nineteen years. I went to Portland, Oregon, to see
Dr. Jacob last July. He started me on a treatment with DMSO. After the
first week, I felt better than I had in nineteen years. I could button my own
clothes, reach behind my head. The pain was almost nothing. Four months
later I no longer had chest pains. I have just come through one more winter and it’s the best winter I’ve
had in six years. I had a few bad points where the 
pain was pretty rough,
but they didn’t last long. Now when I get ulcers I use DMSO and it clears
them up. Also, I didn’t have any more amputations. I feel that now I might
have a chance to see my children grown and to be able to enjoy my
grandchildren. Please help us, we need you to help us fight for a better, pain-free life.THE NEW TREATMENT FOR SCLERODERMA
Lillie Forister was begging for help not only for her own problem but also for the
approximately 150,000 other Americans suffering from scleroderma. While the
disease itself may not immediately kill them, death in adults follows severe and
progressive muscle weakness, difficulty in swallowing, malnutrition, and failure of
the respiratory system with superimposed lung infection, such as pneumonia. And
as they linger, discomfort in general and pain in particular pervade their lives. The victims of scleroderma experience gradual thickening of the skin of the
fingers, aching in most joints, upset of the gut, extreme fatigue, and muscle
wasting. The facial features turn masklike. The skin becomes taut, shiny, and
inflexible on the fingertips, which develop ulcers. The sclerodermatous patient gets
calcification on bony eminences, friction rubs over the knees and tendon sheaths,
and the formation of large bursae. Contractures of the fingers, wrists, and elbows
resulting from skin hardening prevent fine movements, sometimes even gross
movements, such as Jean Puccio’s inability to drive her car. Internally, there is gastric acidity due to an incompetent functioning of the
lower food tube sphincter. Poor absorption from the small intestine occurs from an
overgrowth of anaerobic bacteria. Large pockets or sacs develop in the large
intestine and biliary cirrhosis develops. The lungs don’t work right and defective
gas diffusion results. Heart failure can hit any time and tends to be chronic and to
respond poorly to medication. Kidney disease is a major cause of death in PSS,
usually signaled by sudden high blood pressure that drugs won’t bring down. And for all these symptoms of scleroderma there is no specific treatment. No
drug has proved valuable—nothing was even somewhat effective—until DMSO. “There is no doubt in my mind, the drug relieves certain types of pain. It is not
a curative agent and all the reports we have read about ‘miraculous and
outstanding’ should be completely disregarded. There 
is nothing miraculous about
this compound at all, but it does relieve pain in a temporary manner. It is not a
cure. None of our anti-rheumative drugs are curative. DMSO applied topically is
indeed a safe, therapeutic agent to use,” said Arthur L. Scherbel, M.D., founder of
the Department of Rheumatic Disease at the Cleveland Clinic Foundation in
Cleveland, Ohio, and formerly the department’s senior consultant. In his practice, Dr. Scherbel dealt with patients who have very serious diseases
that are challenges to any form of therapy. He is expert in the pathology of PSS. There are no good, highly effective therapeutic agents for the rheumatic connective
tissue diseases of which scleroderma is one. No drug exists today that iscompletely effective and without toxicity for providing the victims with relief, and
certainly there’s no cure. Dr. Scherbel began using DMSO twenty years ago and found that it blocked
pain for sufferers of scleroderma. This pain relief comes about because the
solvent blocks conduction in the small nerve fibers—C&A delta, the fibers
important in the recognition of pain. If 75 percent DMSO is used directly on the
nerve fibers (in laboratory experiments) and not removed, within two days all
nerve conduction will cease. If 100 percent DMSO is put on these nerves, the
conduction block will occur more rapidly and usually will not be reversible. The
conclusion is that the smaller peripheral nerve fibers, when preferentially blocked
by DMSO, become diminished in their central response to a stimulus that
ordinarily would cause pain. 1
The healing of ulcers occurs, as well, and this is more difficult to explain. Marvin F. Engel, M.D., of Brunswick, Georgia, delivered a paper before the
Section on Dermatology of the Southern Medical Association, at its sixty-fourth
annual meeting in Dallas, Texas, November 18, 1970, where he described how the
skin’s blood vessels look after DMSO use in scleroderma. Dr. Engel said, “One
sees dilatation of vessels in the upper dermis and perhaps the increase in blood
flow plays a role. DMSO is known to protect cells and tissue from freezing,
thawing, necrotic cutaneous changes, inflammatory and hemorrhagic processes.”
2
This protection may be related to cellular physiological enlargement. In a two-year study of twenty sclerodermatous patients, Dr. Engel found
beneficial results using DMSO as the exclusive treatment. He said, “They had
increased mobility, rapid relief of pain and healing of persistent ulcers, arrest of
the spread of cutaneous disease, regrowth of hair, and return of sensation and
sweating. There was absolutely no sign of arrest of systemic disease, as shown by
the death of three 
patients while on therapy and two in the immediate posttreatment
period, despite evidence of improvement of the cutaneous manifestations of their
disorder.”
Dr. Engel also noted that “the maximal activity of DMSO, after it is
swallowed, is in the organs and the parts of organs primarily involved in the
pathologic changes of progressive systemic sclerosis. . . . DMSO might halt or
reverse the process of systemic sclerosis.”
As it relates to the following section, what Dr. Engel added is quite significant:
“No evidence of ocular damage was found by funduscopic or slit lamp
examination in any of our patients.”ALLEGED MISREPORTING OF THE SCHERBEL STUDIES
Dr. Scherbel did similar, more extensive studies on patients having scleroderma,
and he performed them under the FDA supervisory investigational new drug (IND)
application number 10-778. This means the investigator and the sponsoring
pharmaceutical company, Research Industries Corporation, were liable to FDA
regulations. Violations of them would be a federal crime. A statement by Jere E. Goyan, Ph.D., former Commissioner of the FDA, made
before the Senate Subcommittee on Health and Scientific Research, included the
following information:
“We are requiring that eye examinations be conducted as part of any study
involving chronic administration of DMSO in order to obtain additional data to
determine whether the drug causes ocular toxicity. The labeling for the approved
human drug product suggests that patients should receive thorough eye
evaluations, including slit lamp examinations, prior to and periodically during
treatment. . . . We have issued inspection assignments to audit the data of the
scleroderma studies. In all of these investigations our staff is being asked to pay
particular attention to whether or not these studies included eye examinations.”
Dr. Scherbel did his IND 10-778 studies on eleven patients with severe
progressive systemic sclerosis, using DMSO by oral administration. He had them
undergo eye examinations before, during, and after DMSO treatment, in
accordance with FDA rules, for this IND. The patients received a total daily dose
of DMSO ranging from 21 grams to 84 grams in four divided doses diluted in
concentrated juice and crushed ice. The duration of the treatment ranged from 1
month to 22 months with a mean average of 9.4 months. Its results were reported
to Henry Moyle, President of the Research Industries Corporation, Salt 
Lake City,
Utah. In his letter, dated May 4, 1977, Dr. Scherbel advised Mr. Moyle that “in
four of eleven patients reported at this time, nuclear sclerosis or progressive
myopia have appeared during the study.”
This report of lens changes with the development of nearsightedness was
alarming news. It might have caused cessation of the investigation if the FDA had
been aware of the reported eye changes in these patients. Agency officials say that
no one at the FDA knew about them until the information was uncovered, almost
by accident, nearly three years later. Michael J. Hensley, M.D., of the Division of Scientific Investigations, Bureau
of Drugs, FDA, told Senator Kennedy how this came about: “It was not officially
reported, as far as we can tell. We picked up on this during a routine inspection ofDr. Scherbel. . . . On April 22, 1980, I was standing there with an inspection
report in my hand of an oral DMSO study—a study of the use of DMSO orally in
scleroderma—a study wherein patients had been given doses very nearly
approaching the animal studies that had showed ocular toxicity, and it appeared
from the material that we had discovered during this very first, initial tipoff
inspection that the eye changes that were being reported in these patients were
identical to those seen in the animal studies back in the 1960s. . . . It turns out
that the initial report of the oral scleroderma patients had been noted by Dr.
Scherbel to Research Industries on May 4, 1977. . . . It appeared that Research
Industries had reported to them a possible adverse effect in 1977, and yet had
never reported it to the agency because, in our files, we found none of these
reports.”
From the testimony, Senator Kennedy learned that two inspections of the firm
uncovered correspondence that indicated the Scherbel report was received. A
letter from Moyle was sent in reply to Dr. Scherbel’s report indicating that Dr.
Jacob verbally informed K.C. Pani, M.D., an officer of the Division of Anti-
Infective Drug Products of the Bureau of Drugs, FDA, of this finding. Another
letter dated May 17, 1977, from Moyle to Scherbel implied that the Scherbel
report may have been provided to Dr. Pani. At least it said that “Dr. Jacob and I
showed him your letter of May 4, 1977, and Dr. Pani suggested lowering the
DMSO dosage for these patients affected with eye changes.”
Dr. Pani was interviewed, and denied he had ever been told any of this. He
said he was given no letter for the FDA files. Dr. Hensley said, “We therefore had
the possibility of a violation of the Federal Food, Drug, and Cosmetic Act, and
also, perhaps, of title 18, section 1001—the making of false reports to the
Government.”
Compounding this alleged misreporting, on September 7, 1978, 
Moyle wrote
Merle L. Gibson, M.D., Director, Division of Anti-Infective Drug Products,
Bureau of Drugs, a summarized progress report of IND 10-778 saying: “Our
investigations under this IND are still ongoing but to date our investigators have
reported no abnormalities relating to toxicity of the drug, nor have they reported
any ocular abnormalities.
Dmso_Nature_s_Healer_-_Morton_Walker.txt
Summarize the following text section accurately and concisely. Maintain specific details and numerical information, and use anti-repetition mechanisms:

        Another once-a-week adjunctive injection is comprised of 1 cc of ACTH Gel,
40 units per 5 cc bottle or vial;. 5 cc dexamethasone acetate, 4 mg per 30 ccbottle; and. 5 cc triamcinolone acetonide, 40 mg per ml from a 5 ml bottle. A good cancer test is the one for Carcinoma Embryonic Activity (CEA)
performed once a month or more. The normal reading for a non-smoker is 2. 5;
normal for a smoker is 5. 0. Cancer patients taking the DMSO-hematoxylon-dextrose solution should have
kidney function tests of their urine (creatine clearance and BUN) performed
biweekly. They should always drink plenty of fluids. If swelling occurs, the
physician should prescribe Diuril or some other diuretic. Taking vitamin supplements, especially vitamins A, C, E, and D, is essential. Carrots should be eaten every day, in particular for the treatment of liver cancer. Absolutely no liquor, wine, or beer should be consumed. And, realize that smoking
not only retards healing but may have been a contributing source of causing the
condition initially. The DMSO-hematoxylon-dextrose solution should be administered to the
cancer victim daily until a reasonably low CEA test reading is obtained. CASES OF CANCER CURED WITH HEMATOXYLON AND
DMSO
I mentioned that Dr. Tucker had not published the results of his research and
treatment since 1968 because of peer pressure and fear of 
being removed from
medical practice. But this didn’t completely deter him from attempting to heal
those few who made appeals to him for help. For example, two more patients were
successfully treated for large-cell lymphosarcoma. One lived for eight years after
treatment and finally died from a heart attack, as had a previous lymphosarcoma
case. The other is still alive and well today. In the latter case, Alva Ruth Wilson of Porter, Texas, then age thirty-eight,
learned that she was the victim of disseminated large-cell lymphosarcoma in
January 1972. She had sizeable tumors in her lungs, the common iliac arteries, and
the lymph nodes around her aorta. Patients with lymphosarcoma (the kind of cancer that killed the Shah of Iran)
experience a malabsorption syndrome, a clinical state resulting from impaired
assimilation of nutrients from the small bowel. The victim becomes chronically ill
and emaciated, with pale mucous membranes and dry scaly skin that becomes dark
in color. Blood pressure drops. Fluid accumulates in the abdominal cavity, which
swells disproportionately. Anemia develops, and the cancer cells infiltrate thebone marrow. The patient suffers destruction of normal lymph node architecture
and invasion of the node capsules and adjacent fat by characteristic
lymphosarcoma cells. Death in a relatively short time is predictable. Mrs. Wilson had the maximum amount of chemotherapy she could take for one
month and then chemotherapy and radiation together for another month. Still, the
tumors continued to spread and chemotherapy had to be discontinued because of
its awful side effects. One of these was the development of dangerous leukopenia,
a condition in which the total number of white blood cells in the patient’s
circulating blood was far less than normal. She practically lost her immunity to
infection. As a life-threatening chemotherapeutic side effect, Mrs. Wilson’s white
blood count dropped too far below the lower limit of 5,000 per cubic mm. One year later Tucker began hematoxylon and DMSO injections intravenously
for the woman. They were given every other day from January 1973 through
January 1974. All evidence of her tumors disappeared, and they have not recurred
to the present time. Tucker followed Mrs. Wilson’s progress continually; she is
perfectly well today with no side effects from the treatment or from the tumor. In another case, Elroy Guerro of Houston, forty-one years old, had a
lymphosarcoma of three years duration. After full treatment with maximum
radiation and chemotherapy, the opinion of the radiologist was that the patient had
no chance to survive longer than a few more months. He had involvement of the
mediastinal lymph nodes. This patient was treated by intravenous injections of hematoxylon and DMSO,
2. 015 g every other day from December 1971 to March 1972. By the end of the
injection therapy, the tumor had disappeared and Mr. Guerro quit the treatment. Tucker last heard from him in December 1978 and learned that the man was in
excellent condition. There was no evidence of recurrence and no side effects from
the medication. Eventually, when Tucker asked about the patient from his former employer, the
Ideal Engineering Company, the personnel office advised him that Guerro had died
of a heart attack in April 1980, eight years after he had completed the DMSO
treatment for deadly lymphosarcoma. Figure 11. 1
 Photograph of Frank T. Guiddy, age 44; note large tumor
lymphosarcoma of the neck. A third patient was less fortunate. Frank T. Guiddy of Kennedy, New York,
age forty-four, was admitted to Memorial Baptist Hospital in Houston in a terminal
lymphosarcomatous state. He had an obvious tumor, entirely surrounding his neck,
lying just under the skin (see 
Figure 11. 1
). Mr. Guiddy had been treated five years
previously with maximum radiation and chemotherapy. The traditional cancer
treatments 
had brought on severe side effects, mainly absence of white blood cells
in the blood stream. Every day for three weeks, 2. 015 g of hematoxylon and DMSO combination
solution was injected intravenously into the patient. The tumor in his neck
decreased in size from 22. 5 inches (in) to 18. 75 in (see 
Figure 11. 2
), returning
Guiddy’s neck to normal appearance. Unfortunately, this man was so riddled with lymphosarcoma, his body was
totally assaulted by the process. He died at the hospital September 23, 1980. Autopsy showed that he suffered with cancer in almost every organ of his body. Lymphosarcoma involved the man’s cervical lymph nodes, retroperitoneal and
abdominal nodes, membranes around his heart, pancreas, left and right lungs,
spleen, the entire gastrointestinal tract, kidneys, adrenal glands, and especially his
liver, which weighed an immense 3,400 g. He died in bed from liver failure a week
after the photograph shown in 
Figure 11. 2
 was taken. His liver was a solid mass of
dead lymphosarcoma. The DMSO-hematoxylon material had enough anti-tumor
quality to destroy the enormous 
masses of lymphosarcomatous growth permeating
the man’s body. If Guiddy had had near-normal organs or at least a functioning
liver, it’s likely he would have survived. But he did not.
Not mentioned in the passage.
What is the composition of the ACTH Gel, dexamethasone acetate, and triamcinolone acetonide?
2.5
What is the normal CEA reading for a non-smoker?
Not mentioned in the passage
What is the recommended dose for treating herpes zoster?
To treat respiratory infections in children
What is the purpose of the English study on the use of DMSO spray?
The alleged violation is the failure to report the eye changes in the patients to the FDA.
What is the alleged violation of the Federal Food, Drug, and Cosmetic Act, as reported by the FDA?